Published in Eur J Heart Fail on August 01, 2010
Spectrum of cardiac disease in maternity in a low-resource cohort in South Africa. Heart (2014) 2.15
Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med (2015) 1.54
Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol (2013) 1.20
Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J (2015) 1.09
Peripartum cardiomyopathy: a review. Tex Heart Inst J (2012) 1.06
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol (2015) 0.99
New insights in prolactin: pathological implications. Nat Rev Endocrinol (2015) 0.98
Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol (2011) 0.96
Incidence and predictors of maternal cardiovascular mortality and severe morbidity in The Netherlands: a prospective cohort study. PLoS One (2013) 0.94
Heart failure in sub-Saharan Africa. Curr Cardiol Rev (2013) 0.94
Cardiovascular Disease in Women: Clinical Perspectives. Circ Res (2016) 0.92
Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail (2011) 0.92
Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc (2014) 0.92
Role of echocardiography in the management of cardiac disease in women. J Cardiovasc Ultrasound (2014) 0.92
Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clin Res Cardiol (2015) 0.91
Peripartum Cardiomyopathy in Intensive Care Unit: An Update. Front Med (Lausanne) (2015) 0.87
Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail (2013) 0.86
Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. Clin Res Cardiol (2015) 0.86
Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev (2014) 0.85
The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr (2012) 0.85
Clinical characteristics and risk factors for peripartum cardiomyopathy. Afr Health Sci (2012) 0.83
Pregnancy-Associated Heart Failure: A Comparison of Clinical Presentation and Outcome between Hypertensive Heart Failure of Pregnancy and Idiopathic Peripartum Cardiomyopathy. PLoS One (2015) 0.82
The Wearable Cardioverter/Defibrillator - Toy Or Tool? J Atr Fibrillation (2016) 0.82
Peripartum cardiomyopathy: a contemporary review. Methodist Debakey Cardiovasc J (2013) 0.80
Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy. Int J Mol Sci (2015) 0.80
Reversible cushing dilated cardiomyopathy mimicking peripartum cardiomyopathy with successful subsequent pregnancy. BMJ Case Rep (2011) 0.79
Peripartum cardiomyopathy: moving towards a more central role of genetics. Curr Cardiol Rev (2013) 0.79
One Year Survival in Nigerians with Peripartum Cardiomyopathy. Heart Views (2016) 0.79
Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study. BMC Cardiovasc Disord (2016) 0.79
Peripartum cardiomyopathy: ten year experience at a tertiary care hospital in Pakistan. BMC Res Notes (2013) 0.78
Peripartum cardiomyopathy: a review. Int J Womens Health (2012) 0.78
Peripartum cardiomyopathy: Euro Observational Research Program. Neth Heart J (2014) 0.78
Peripartum cardiomyopathy in a woman with preeclampsia with twin pregnancy. BMJ Case Rep (2014) 0.78
Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Fail (2015) 0.77
In-hospital management and outcomes in patients with peripartum cardiomyopathy: a descriptive study using a national inpatient database in Japan. Heart Vessels (2017) 0.77
A change of heart: case series of peripartum cardiomyopathy. Case Rep Obstet Gynecol (2013) 0.77
Focus on pregnancy-mediated heart and vascular disease. Cardiovasc Res (2014) 0.77
Hypertension and hypertensive heart disease in African women. Clin Res Cardiol (2014) 0.76
Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine. Case Rep Med (2012) 0.76
Descriptive epidemiology and short-term outcomes of heart failure hospitalisation in rural Haiti. Heart (2016) 0.76
Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J (2017) 0.76
Commentary: Peripartum Cardiomyopathy in Intensive Care Unit: An Update. Front Med (Lausanne) (2016) 0.75
Electrocardiographic predictors of peripartum cardiomyopathy. Cardiovasc J Afr (2016) 0.75
Gestational Weight Gain and Peripartum Cardiomyopathy in a Twin Pregnancy. Case Rep Obstet Gynecol (2015) 0.75
Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int (2016) 0.75
All that wheezes is not asthma: A cautionary case study of shortness of breath in pregnancy. Obstet Med (2015) 0.75
Abnormal maternal echocardiographic findings in triplet pregnancies presenting with dyspnoea. Wien Klin Wochenschr (2016) 0.75
Peripartum Cardiomyopathy Presenting as Bradycardia. Case Rep Obstet Gynecol (2017) 0.75
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovasc Res (2017) 0.75
Successful Treatment of Peripartum Cardiomyopathy with Plasmapheresis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.75
Increased glucocorticoid receptor expression in sepsis is related to heat shock proteins, cytokines, and cortisol and is associated with increased mortality. Intensive Care Med Exp (2017) 0.75
[Special features of peripartum cardiomyopathy in Africa: the case of Togo on a prospective study of 41 cases at Sylvanus Olympio University Hospital of Lome]. Pan Afr Med J (2014) 0.75
Endomyocardial biopsy via the femoral access - still safe and valuable diagnostic tool. BMC Cardiovasc Disord (2016) 0.75
The importance of cardiovascular pathology contributing to maternal death: Confidential Enquiry into Maternal Deaths in South Africa, 2011-2013. Cardiovasc J Afr (2016) 0.75
Response to Adam Morton's Letter 'Reply to: Timothy A C Snow, Cara AWasywich and Fiona M Stewart. A case of breathlessness during pregnancy: the difficulty in diagnosing heart failure'. Obstet Med (2013) 0.75
Experiences of health care in women with Peripartum Cardiomyopathy in Sweden: a qualitative interview study. BMC Pregnancy Childbirth (2016) 0.75
Comparison of clinical outcomes in peripartum cardiomyopathy and age-matched dilated cardiomyopathy: A 15-year nationwide population-based study in Asia. Medicine (Baltimore) (2017) 0.75
Practical management of peripartum cardiomyopathy. Korean J Intern Med (2017) 0.75
Clinical Profi le and Predictors of Outcomes of Patients with Peripartum Cardiomyopathy: The Philippine Heart Center Experience. ASEAN Heart J (2016) 0.75
Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not? Obstet Med (2013) 0.75
A microRNA links prolactin to peripartum cardiomyopathy. J Clin Invest (2013) 0.75
Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump. Clin Res Cardiol (2012) 0.75
Physiological Reduction in Left Ventricular Contractile Function in Healthy Postpartum Women: Potential Overlap with Peripartum Cardiomyopathy. PLoS One (2016) 0.75
Prevalence and Aetiology of Left Ventricular Thrombus in Patients Undergoing Transthoracic Echocardiography at the University of Maiduguri Teaching Hospital. Adv Med (2014) 0.75
Peripartum cardiomyopathy. Ann Med Health Sci Res (2013) 0.75
GNB3 C825T Polymorphism and Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter Investigations of Pregnancy-Associated Cardiomyopathy Study. Circ Heart Fail (2016) 0.75
Reversion of Severe Mitral Insufficiency in Peripartum Cardiomyopathy Using Levosimendan. J Clin Med Res (2015) 0.75
Immunosuppression therapy in the management of peripartum cardiomyopathy: A case series and literature review. Obstet Med (2016) 0.75
A Case of Breathlessness during Pregnancy: The Difficulty in Diagnosing Heart Failure. Obstet Med (2013) 0.75
Severe dyspnoea during late pregnancy in a woman with history of asthma. Clin Res Cardiol (2011) 0.75
Vasoinhibins May Contribute to Postpartum Depression. Front Psychiatry (2017) 0.75
Overview of current surgical strategies for aortic disease in patients with Marfan syndrome. Surg Today (2015) 0.75
Subsequent Safe Pregnancy with Cesarean Delivery in a Patient with a History of Peripartum Takotsubo Syndrome Complicated by Cardiogenic Shock. J Cardiovasc Echogr (2017) 0.75
Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol (2017) 0.75
The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy. Clin Res Cardiol (2014) 0.75
Cardiomyopathies and anaesthesia. Indian J Anaesth (2017) 0.75
Prevalence and predictors of right ventricular diastolic dysfunction in peripartum cardiomyopathy. J Echocardiogr (2017) 0.75
Heart Disease and Pregnancy. Cardiol Ther (2017) 0.75
Peripartum cardiomyopathy, what if your patient plans to reconceive? Clin Case Rep (2017) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol (2005) 5.63
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J (2011) 5.11
Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet (2009) 4.97
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Stillbirths: what difference can we make and at what cost? Lancet (2011) 4.50
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J (2006) 3.55
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49